

HETEROCYCLES, Vol. 70, 2006, pp. 185 - 199. © The Japan Institute of Heterocyclic Chemistry
Received, 11th May, 2006, Accepted, 14th June, 2006, Published online, 20th June, 2006. COM-06-S(W)3

STRECKER REACTIONS OF CHIRAL *N*-ACYLHYDRAZONES


Hui Ding and Gregory K. Friestad*

Department of Chemistry, University of Iowa, Iowa City, Iowa, 52242 and
Department of Chemistry, University of Vermont, Burlington, Vermont, 05405,
U. S. A.

Abstract – Development of a method for addition of trimethylsilyl cyanide to chiral oxazolidinone-derived *N*-acylhydrazones is described. The diastereoselectivity was found to be highly dependent on the substituent of the oxazolidinone moiety; 4-phenyl-2-oxazolidinone achieved much higher stereocontrol than four other oxazolidinones screened. The reaction gives modest selectivity with aliphatic hydrazones and excellent selectivity with hydrazones prepared from aromatic aldehydes.

INTRODUCTION


Strecker-type cyanide addition to C=N bonds affords straightforward access to α -amino nitrile compounds, which offer a broad range of synthetic applications, mainly by hydrolysis, reduction or alkylation reactions of the nitrile group.¹ Recent interests on synthesis of unusual α -amino acids as key building blocks for pharmaceuticals have prompted intense investigation of the asymmetric Strecker-type reaction.² Highly efficient catalytic processes have been developed for asymmetric Strecker-type cyanation of imines; these have been based on organocatalysts,³ phase transfer catalysts,⁴ and metal Lewis acid catalysts.⁵



Scheme 1. The Strecker reaction and its utility

Use of enantiopure chiral auxiliaries offers a practical alternative wherein the intermediate diastereomer separation facilitates general access to rigorously enantiopure compounds, even in cases where the selectivity may not be optimal. Effective auxiliaries have been reviewed extensively,^{1,2} and selected examples include α -substituted ethylamines,⁶ 1,2-amino alcohols,⁷ carbohydrate derivatives,⁸ and sulfinimines.⁹ Important biologically active α,α -dialkyl amino acids have been obtained with high selectivity using an acyloxy amino acid as a chiral auxiliary.¹⁰ Diastereoselective Strecker reactions have also been accomplished by crystallization-induced asymmetric transformations of carbonyl compounds in the presence of chiral amines and cyanide donors.¹¹

Among all the previous work noted above, there have been only sporadic reports regarding *N*-acylhydrazones as substrates for asymmetric Strecker-type cyanation. With their ease of preparation, increased air and hydrolytic stability, *N*-acylhydrazones are superior imine surrogates.¹² In 2004, Jacobsen reported asymmetric hydrocyanation to *N*-acylhydrazones catalyzed by lanthanide-PYBOX complexes.¹³ Although good selectivity was observed for some aromatic and aliphatic aldehyde hydrazones, the scope is still limited to electron-rich hydrazones. More recently, Kobayashi has reported catalytic procedures for dual activation¹⁴ in racemic cyanation of *N*-acylhydrazones.¹⁵ Chiral *N,N*-dialkylhydrazones, prepared from (*S*)-1-amino-2-methoxymethylindoline (SAMI)¹⁶ and (*S*)-1-amino-2-methoxymethyl-pyrrolidine (SAMP),¹⁷ have also been used for Strecker-type reactions. However, the use of chiral *N*-acylhydrazones in Strecker reactions has not previously been reported.




Scheme 2. General chiral *N*-acylhydrazone approach

Our recent studies have revealed *N*-acylhydrazones derived from chiral oxazolidinones¹⁸ are excellent substrates for asymmetric nucleophilic additions of hydride¹⁹ and allylsilane²⁰ reagents to C=N bonds.^{21,22} The design of these chiral imino acceptors incorporates bidentate Lewis acid binding for efficient electrophilic activation and restriction of rotamer populations (Scheme 2). Following our initial studies, several applications of these chiral *N*-acylhydrazones to a variety of other addition reactions have been reported.²³ Inspired by the potential to build a general suite of reaction types around the general chiral *N*-acylhydrazone approach indicated in Scheme 2, we embarked on a study of their application in asymmetric Strecker-type reactions, and here we disclose the results of this methodology study.

RESULTS AND DISCUSSION

To initiate the study, the effects of Lewis acids on TMSCN addition were examined using prototype hydrazone (**2a**)²² (Table 1). A control experiment established that **2a** does not react with TMSCN in the absence of Lewis acid (Entry 1). Based on the previous success with In(III) Lewis acids,^{20,22b} several In(III) salts were screened. The hydrazone was indeed activated by In(OTf)₃, resulting in a good yield of α -amino nitrile (**3a**) (Entry 2). Comparison of In(III) halides showed that the counterion was important; InCl₃ was somewhat less active than the corresponding triflate, while InF₃ was inactive (Entries 3 and 4).²⁴ Nucleophilic activation of the TMSCN with tetrabutylammonium triphenyldifluorosilicate²⁵ (TBAT) as fluoride source also promoted the reaction in the presence of In(OTf)₃ (Entry 5), but the yield and diastereoselectivity were not competitive with In(OTf)₃ alone.

Table 1. Additions with variation of Lewis acid



Entry	Additives	Solvent	Conversion, % ^a	3a , % ^b	dr ^c
1	None	CH ₂ Cl ₂	0	0	--
2	In(OTf) ₃		86	77	67:33
3	InCl ₃		62	48	55:45
4	InF ₃		0	0	--
5	In(OTf) ₃ , TBAT ^d		91	59	63:37
6	In(OTf) ₃	CH ₃ CN	91	78	52:48
7		THF	89	67	55:45
8		Et ₂ O	82	41	55:45
9		DMF	nd ^e	0	--


^a Calculated from recovered hydrazone(**2a**). ^b Percent isolated yield of **3a**. ^c Diastereomer ratio, determined by ¹H NMR spectra prior to chromatography. ^d TBAT = tetrabutylammonium triphenyldifluorosilicate. ^e nd = not determined

Consistent with precedent,^{8,17} a solvent dependence was also observed under these conditions (Entries 6–9). Decreased diastereomer ratios and moderate yields were observed in acetonitrile, diethyl ether and THF, whereas the reaction did not occur in DMF. A possible explanation is the interference with the two-point-binding complex (Scheme 2) by more polar solvents.

Based on the above results, the optimal conditions of (Table 1, Entry 2: 1.3 equiv In(OTf)₃ in CH₂Cl₂) were applied for screening of auxiliaries (Table 2). For most of the oxazolidinones, yields of cyanide adducts were in a useful range (up to 77%), but the diastereomeric ratios never exceeded 3:1. Beyond the point of attachment, it seems that the size of the substituent on the oxazolidinone moiety does not

affect selectivity (compare Entries 2 and 3). This is in sharp contrast to the observations with radical additions to a related series of hydrazones; in those reactions all of the auxiliaries were quite effective.

Table 2. Additions with variation of oxazolidinones



Entry	Substrate	R of X*	Conversion, % ^a	Yield, % ^b	dr ^{c,d}
1	2a	CH ₂ Ph	86	77 (3a)	67:33
2	2b	<i>i</i> -Pr	87	65 (3b)	60:40
3	2c	CHPh ₂	72	44 (3c)	67:33
4	2d		93	72 (3d)	73:27
5	2e	Ph	77	46 (3e)	>99:1


^a Calculated based on recovered substrate. ^b Percent isolated yield. ^c Diastereomer ratio, determined by ¹H NMR spectra of product mixtures prior to chromatography. ^d Configurations assigned by analogy with **3l** (see eq 3).

Fortunately, there was a dramatic difference with the hydrazone (**2e**) derived from (*S*)-4-phenyl-2-oxazolidinone, which provided excellent diastereoselectivity (>99:1 dr, 2 days, Entry 5), albeit with moderate yield. Control experiments showed longer reaction time (7 days, 48% yield with 26% of hydrazone recovered) or increased TMSCN (10 equiv, 36% yield) did not improve the yields. A possible explanation for the anomalous stereoselectivity with **2e** is in the very small steric requirement of the linear CN[−] anion, such that the sp²-hybridized phenyl substituent of **2e** with unrestricted conformation (in comparison to **2d**) is the only one which can effectively block access to the imino carbon.

With outstanding stereoselectivity at hand, a survey of scope was undertaken using a series of hydrazones, which were prepared from the corresponding aldehydes in excellent yields for the two-step sequence by our standard procedure²⁶ (Scheme 3).


When subjected to the standard conditions, neutral or moderately electron-rich aromatic aldehyde hydrazones gave modest yields but excellent diastereoselectivities (Table 3, Entries 1-3). Electron-deficient *m*-nitrobenzaldehyde, the hydrazone of which has been previously found unreactive with TMSCN,¹³ also participated in the reaction via hydrazone (**2h**) (Entry 4) to give a moderate yield of **3h**, but the selectivity dropped dramatically to 1.5:1. With a strong electron-donating group, there was very low isolated yield of **3i** (Entry 5), but this was in contrast to the good conversion detected by TLC,

suggesting the low yield may result from decomposition of the α -amino nitrile during purification. Interestingly, (*E*)-cinnamyl aldehyde hydrazone (**2j**) (Entry 6) was unreactive. On the other hand, aliphatic hydrazones (**2k**) and (**2l**) (Entries 7 and 8) participated in the reaction with modest diastereoselectivity. At $-55\text{ }^{\circ}\text{C}$, selectivity of addition to **2l** improved slightly (not shown), but reaction rate at this temperature was too slow to be practical.



Scheme 3. Preparation of chiral *N*-acylhydrazones


Table 3. Scope of addition of TMSCN to chiral *N*-acylhydrazones



Entry	Hydrazone	R	Conversion, % ^a	Yield, % ^b	dr ^{c,d}
1	2e	Ph	77	46 (3e)	>99:1
2	2f	2-naphthyl	80	41 (3f)	>95:5
3	2g	4-methylphenyl	82	34 (3g)	>99:1
4	2h	3-nitrophenyl	100	53 (3h)	60:40
5	2i	4-methoxyphenyl	92	5 (3i)	>95:5
6	2j	(<i>E</i>)-cinnamyl	58	0 (3j)	--
7	2k	ethyl	100	37 (3k)	67:33
8	2l	isopropyl	100	73 (3l)	75:25

^a Based on recovery of **2** after chromatography. ^b Isolated yield of **3**. ^c Diastereomer ratio of **3** measured by ¹H NMR spectrometry prior to chromatography. ^d Configurations assigned by analogy with **3l** (see eq 3).

The role of electronic properties in determining selectivity in the case of **2h** calls for further discussion. There are several reasonable explanations for the much lower selectivity in cyanation of the *m*-nitrobenzaldehyde hydrazone (**2h**). The strong electron-withdrawing effect of the nitro group would



In conclusion, examination of Strecker-type reaction of chiral *N*-acylhydrazones derived from various 2-oxazolidinones revealed an unusual dependence of diastereoselectivity on the oxazolidinone substituent. Using (*S*)-4-phenyl-2-oxazolidinone, excellent diastereomeric ratios favoring the (*R*)-aminonitrile were obtained for aromatic aldehyde hydrazones, with the exception of the hydrazone from 3-nitrobenzaldehyde. Aliphatic aldehyde hydrazones afforded modest diastereoselectivities. Improved yields are required for practical application, but this study achieves excellent stereocontrol in Strecker reactions of aromatic chiral *N*-acylhydrazones. From a broader perspective, this work extends the general utility of the chiral *N*-acylhydrazones and their application for acyclic stereocontrol.

EXPERIMENTAL

Known hydrazones (**2a–2e**)¹⁸ and new hydrazones (**2f–2l**) were prepared according to General Procedure A from the appropriate substituted 3-amino-2-oxazolidinones.

Preparation of enantiopure *N*-acylhydrazones (General Procedure A): To a solution of the appropriate substituted (*S*)-3-amino-2-oxazolidinone (ca. 1 mmol) in toluene (ca. 0.1 M) was added MgSO_4 (200 mg), a catalytic amount of *p*-TsOH (ca. 5 mol %) and aldehyde (ca. 1.5 equiv). After heating at reflux for 10 min, concentration and flash chromatography (5:1 hexane/ethyl acetate) gave pure hydrazones.

(*S*)-3-(2-Naphthylmethylene)amino-4-phenyloxazolidin-2-one (2f). From 2-naphthaldehyde (0.19 g, 1.2 mmol) by General Procedure A was obtained **2f** (0.28 g, 88%) as a colorless solid; mp 234–236 °C; $[\alpha]_{\text{D}}^{25} +145$ (c 0.15, CHCl_3); IR (film): 3041, 2988, 2923, 1765, 1752, 1457, 1405, 1311, 1225, 1098, 1024 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.03 (s, 1H), 7.89 (d, $J = 8.6$ Hz, 1H), 7.78–7.72 (m, 4H), 7.45–7.34 (m, 7H), 5.33 (dd, $J = 8.9, 5.8$ Hz, 1H), 4.80 (dd, $J = 8.8, 8.8$ Hz, 1H), 4.21 (dd, $J = 8.7, 5.8$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.6, 147.3, 137.1, 134.4, 133.0, 131.6, 129.7, 129.1, 128.3, 127.9, 127.1, 126.5, 126.0, 69.7, 59.5; MS (EI) m/z (relative intensity): 316 (M^+ , 20%); Anal. Calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2$: C, 75.93; H, 5.10; N, 8.86. Found: C, 76.00; H, 5.25; N, 8.66.

(*S*)-3-(4-Methylbenzylidene)amino-4-phenyloxazolidin-2-one (2g). From *p*-methylbenzaldehyde (0.23

g, 1.1 mmol) by General Procedure A was obtained **2g** (0.26 g, 91%) as a colorless solid; mp 156–158 °C; $[\alpha]_D^{25} +63$ (*c* 0.19, CHCl₃); IR (film): 3034, 3001, 2916, 1770, 1752, 1560, 1456, 1401, 1320, 1303, 1208, 1096, 1030 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.84 (s, 1H), 7.45–7.08 (m, 9H), 5.28 (dd, *J* = 8.9, 5.7 Hz, 1H), 4.76 (dd, *J* = 8.8, 8.8 Hz, 1H), 4.17 (dd, *J* = 8.8, 5.7 Hz, 1H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.6, 147.5, 140.6, 137.2, 131.1, 129.6, 129.3, 129.0, 127.5, 126.0, 69.6, 59.4, 21.4; MS (EI) *m/z* (relative intensity): 280 (M⁺, 73%); Anal. Calcd for C₁₇H₁₆N₂O₂: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.23; H, 5.82; N, 9.64.

(S)-3-(3-Nitrobenzylidene)amino-4-phenyl-oxazolidin-2-one (2h). From *m*-nitrobenzaldehyde (0.168 g, 1.10 mmol) by General Procedure A was obtained **2h** (0.28 g, 89%) as a colorless solid; mp 124–126 °C; $[\alpha]_D^{23} +106$ (*c* 0.14, CHCl₃); IR (film): 3089, 2917, 1771, 1617, 1532, 1473, 1400, 1209, 1095 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.22 (d, *J* = 1.5 Hz, 1H), 7.91 (d, *J* = 4.4 Hz, 1H), 7.41–7.31 (m, 8H), 5.37 (dd, *J* = 8.8, 5.5 Hz, 1H), 4.84 (dd, *J* = 8.8, 8.8 Hz, 1H), 4.21 (dd, *J* = 8.8, 5.4 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 148.5, 143.8, 136.6, 135.7, 132.6, 129.8, 129.6, 129.3, 126.0, 124.5, 122.2, 69.9, 59.3; MS (EI) *m/z* (relative intensity): 311 (M⁺, 9%); Anal. Calcd for C₁₆H₁₃N₃O₄: C, 61.73; H, 4.21; N, 13.50. Found: C, 61.99; H, 4.42; N, 13.04.

(S)-3-(4-Methoxybenzylidene)amino-4-phenyloxazolidin-2-one (2i). From *p*-methoxybenzaldehyde (0.13 mL, 1.1 mmol) by General Procedure A was obtained **2i** (0.28 g, 95%) as a colorless solid; mp 162–164 °C; $[\alpha]_D^{25} +71$ (*c* 0.5, CHCl₃); IR (film): 3034, 2975, 2916, 2844, 1760, 1607, 1514, 1405, 1253, 1171, 1089, 1027 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (s, 1H), 7.50 (d, *J* = 8.6 Hz, 1H), 7.45–7.30 (m, 6H), 6.80 (d, *J* = 8.5 Hz, 2H), 5.27 (dd, *J* = 8.9, 5.9 Hz, 1H), 4.76 (dd, *J* = 8.9, 8.9 Hz, 1H), 4.16 (dd, *J* = 8.9, 5.9 Hz, 1H), 3.77 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.5, 154.7, 147.7, 137.3, 129.6, 129.1, 128.9, 126.6, 126.1, 114.0, 69.5, 59.7, 55.4; MS (CI) *m/z* (relative intensity): 297 ([M+1]⁺, 100%); HRMS-FAB (*m/z*) [M+H]⁺ Calcd for C₁₇H₁₇N₂O₃, 297.1239; found, 297.1239.

(S)-3-(3-Phenyl-2-(E)-propenylidene)amino-4-phenyloxazolidin-2-one (2j). From *trans*-cinnamaldehyde (0.13 mL, 1.0 mmol) by General Procedure A was obtained **2j** (0.26 g, 89%) as a colorless solid; mp 154–157 °C; $[\alpha]_D^{22} +106$ (*c* 0.1, CHCl₃); IR (film): 3033, 2982, 2923, 1757, 1627, 1456, 1407, 1338, 1232, 1089, 1037, 978 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.66 (d, *J* = 7.8 Hz, 1H), 7.43–7.26 (m, 10H), 6.89 (dd, *J* = 16.0, 9.0 Hz, 1H), 6.64 (d, *J* = 16.0 Hz, 1H), 5.24 (dd, *J* = 8.7, 5.6 Hz, 1H), 4.76 (dd, *J* = 8.8, 8.8 Hz, 1H), 4.16 (dd, *J* = 8.7, 5.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.6, 148.9, 139.8, 136.9, 135.7, 129.7, 129.1, 129.0, 128.8, 127.0, 125.9, 125.3, 69.8, 59.2; MS (EI) *m/z* (relative intensity): 292 (M⁺, 7%); Anal. Calcd for C₁₈H₁₆N₂O₂: C, 73.95; H, 5.52; N, 9.58. Found: C, 73.50; H, 5.33; N, 9.55.

(S)-4-Phenyl-3-(propylideneamino)oxazolidin-2-one (2k). From propionaldehyde (0.09 mL, 1.2 mmol) by General Procedure A was obtained **2k** (0.14 g, 64%) as a colorless solid; mp 92–94 °C; $[\alpha]_D^{20} +112$ (*c*

0.59, CHCl_3); IR (film): 2973, 2936, 1772, 1527, 1458, 1403, 1323, 1210, 1094, 1038, 917 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.38–7.12 (m, 6H), 5.13 (dd, $J = 8.5, 5.9$ Hz, 1H), 4.69 (dd, $J = 8.8, 8.5$ Hz, 1H), 4.08 (dd, $J = 8.5, 5.9$ Hz, 1H), 2.25–2.16 (m, 2H), 0.90 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.9, 153.2, 137.0, 129.5, 128.9, 125.9, 69.6, 59.1, 26.2, 10.8; MS (CI) m/z (relative intensity): 219 ($[\text{M}+1]^+$, 100%); Anal. Calcd for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_2$: C, 66.04; H, 6.47; N, 12.84. Found: C, 65.96; H, 6.30; N, 12.77.

(S)-3-Isobutylideneamino-4-phenyloxazolidin-2-one (2l). From isobutyraldehyde (0.2 mL, 2.2 mmol) by General Procedure A was obtained **2l** (0.33 g, 70%) as a colorless solid; mp 110–112 $^\circ\text{C}$; $[\alpha]_{\text{D}}^{23} +102$ (c 0.24, CHCl_3); $[\alpha]_{\text{D}}^{20} +127$ (c 0.62, CHCl_3); IR (film): 2967, 2873, 1767, 1529, 1483, 1460, 1399, 1220, 1104, 1026 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.37–7.22 (m, 4H), 6.96 (d, $J = 5.8$ Hz, 1H), 5.14 (dd, $J = 8.4, 5.7$ Hz, 1H), 4.69 (dd, $J = 8.8, 8.8$ Hz, 1H), 4.08 (dd, $J = 8.8, 5.8$ Hz, 1H), 2.50–2.41 (m, 1H), 0.85 (d, $J = 6.8$ Hz, 3H), 0.80 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.3, 154.9, 136.9, 126.5, 128.9, 126.0, 69.4, 59.1, 31.9, 19.77, 19.74; MS (EI) m/z (relative intensity): 232 (M^+ , 31%); Anal. Calcd for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_2$: C, 67.22; H, 6.94; N, 12.06. Found: C, 66.44; H, 6.85; N, 11.85.

Strecker Reaction (General Procedure B): A mixture of the hydrazone (0.2 mmol) and $\text{In}(\text{OTf})_3$ (0.26 mmol) in CH_2Cl_2 (2.5 mL) was stirred at ambient temperature for 4 h. To the resulting solution was added TMSCN (0.08 mL, 0.6 mmol) by syringe. After 2 d at ambient temperature the reaction was quenched by addition of saturated NaHCO_3 solution (2 mL). The organic phase was separated, and the aqueous phase was extracted with CH_2Cl_2 . The organic phases were combined, washed with brine, and dried over MgSO_4 . Filtration, concentration and flash chromatography (hexane/EtOAc) gave α -hydrazinonitriles (**3a–3l**). Solid products were recrystallized from isopropanol to give colorless crystals. Infrared data for **3a–3l** showed very weak (sometimes undetected) absorbance in the region from 2210–2260 cm^{-1} , as expected for α -aminonitriles.²⁹

2-[(S)-(4-Benzyl-2-oxooxazolidin-3-yl)amino]-2-phenylacetonitrile (3a). From **2a** (56 mg, 0.2 mmol) by General Procedure B was obtained **3a** as a colorless oil, inseparable 2:1 mixture of diastereomers; IR (film): 3273, 3030, 2912, 2252 (w), 1760, 1603, 1496, 1454, 1237, 1104, 1026 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.70–7.10 (m, 10H), 5.31 (d, $J = 2.9$ Hz, 0.33H), 5.25 (d, $J = 2.9$ Hz, 0.67H), 4.45–4.43 (m, 1H), 4.24 (dd, $J = 8.0, 8.0$ Hz, 0.67H), 4.20–4.14 (m, 0.67H), 4.09–4.01 (m, 1.33H), 3.73–3.66 (m, 0.33H), 3.48 (dd, $J = 13.6, 3.7$ Hz, 0.33H), 3.22 (dd, $J = 13.6, 3.7$ Hz, 0.67H), 2.76 (dd, $J = 13.6, 9.8$ Hz, 0.33H), 2.55 (dd, $J = 13.6, 9.5$ Hz, 0.67H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.3 (minor), 158.1 (major), 135.5 (minor), 135.3 (major), 131.9 (minor), 131.6 (major), 130.2, 129.4, 129.2, 129.0 (major), 128.9 (minor), 128.6 (minor), 128.5 (major), 127.3 (minor), 127.2 (major), 118.2 (major), 118.1 (minor), 67.5 (minor), 66.3 (major), 59.6 (minor), 58.8 (major), 55.8 (minor), 55.7 (major), 38.0 (minor), 36.7 (major); MS (EI) m/z (relative intensity): 307 (M^+ , 1%).

2-[(S)-(4-Isopropyl-2-oxooxazolidin-3-yl)amino]-2-phenylacetonitrile (3b). From **2b** (44 mg, 0.19 mmol) by General Procedure B was obtained **3b** as a 1.5:1 mixture of diastereomers (32 mg, 65%, major diastereomer separable); **Major**: colorless oil. $[\alpha]_{\text{D}}^{20}$ -87 (c 0.35, CHCl_3); IR (film): 3272, 2964, 2877, 2250 (w), 1756, 1483, 1456, 1406, 1220, 1100 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.57-7.41 (m, 5H), 5.24 (d, $J = 2.7$ Hz, 1H), 4.35 (dd, $J = 8.7, 8.7$ Hz, 1H), 4.25 (d, $J = 2.4$ Hz, 1H), 4.11 (dd, $J = 9.1, 4.3$ Hz, 1H), 3.98 (dd, $J = 8.2, 4.0$ Hz, 1H), 2.28-2.22 (m, 1H), 0.90 (d, $J = 7.0$ Hz, 3H), 0.81 (d, $J = 6.9$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.3, 131.5, 130.2, 129.4, 128.5, 118.4, 63.6, 61.4, 55.6, 28.9, 27.9, 17.6, 15.3; MS (EI) m/z (relative intensity): 259 (M^+ , 3%); Anal. Calcd for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_2$: C, 64.85; H, 6.61; N, 16.21. Found: C, 64.93; H, 6.62; N, 16.02.

2-[(S)-(4-Diphenylmethyl-2-oxooxazolidin-3-yl)amino]-2-phenylacetonitrile (3c). From **2c** (36 mg, 0.1 mmol) by General Procedure B was obtained **3c** (17 mg, 44%) as a colorless solid, inseparable 2:1 mixture of diastereomers; IR (film): 3283, 3060, 2922, 1759, 1652, 1593, 1494, 1216, 1102, 1023 cm^{-1} ; **Major**: ^1H NMR (500 MHz, CDCl_3) δ 7.36-7.11 (m, 15H), 4.97-4.93 (m, 1H), 4.85 (d, $J = 4.8$ Hz, 1H), 4.42-4.34 (m, 2H), 4.19-4.15 (m, 1H), 4.08-4.03 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.1, 140.5, 139.3, 131.8, 131.1, 129.1, 129.0, 128.8, 128.6, 128.3, 127.6, 127.2, 126.9, 118.2, 65.9, 60.0, 55.3, 54.1; MS (EI) m/z (relative intensity): 383 (M^+ , 4%); Anal. Calcd for $\text{C}_{24}\text{H}_{21}\text{N}_3\text{O}_2$: C, 75.18; H, 5.52; N, 10.96. Found: C, 75.08; H, 5.74; N, 10.61.

2-Hydrazino phenylacetonitrile (3d). From **2d** (56 mg, 0.2 mmol) by General Procedure B was obtained **3d** (44 mg, 72%) as a separable 2.7:1 mixture of diastereomers; **Major**: colorless oil; $[\alpha]_{\text{D}}^{20}$ $+39$ (c 0.1, CHCl_3); IR (film): 3276, 3071, 3031, 2932, 2248 (w), 1754, 1650, 1459, 1383, 1201, 1113, 1032 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.62-7.20 (m, 9H), 5.39-5.34 (m, 2H), 5.31 (d, $J = 2.2$ Hz, 1H), 4.29(s, 1H), 3.41-3.29 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.5, 140.0, 137.6, 131.4, 130.2, 129.8, 129.4, 128.5, 127.6, 126.1, 125.5, 118.5, 77.8, 65.3, 55.9, 38.3; MS (EI) m/z (relative intensity): 305 (M^+ , 1%); Anal. Calcd for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_2$: C, 70.81; H, 4.95; N, 13.76. Found: C, 70.42; H, 5.01; N, 13.46. **Minor**: colorless oil; $[\alpha]_{\text{D}}^{20}$ $+37$ (c 0.04, CHCl_3); IR (film): 3275, 3034, 2924, 2248 (w), 1752, 1458, 1384, 1202, 1115, 1034 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.61-7.23 (m, 9H), 5.27 (d, $J = 4.1$ Hz, 1H), 5.08 (ddd, $J = 7.1, 7.1, 2.2$ Hz, 1H), 4.69 (d, $J = 4.1$ Hz, 1H), 4.62 (d, $J = 7.0$ Hz, 1H), 3.34-3.23 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.4, 140.0, 137.4, 132.5, 130.1, 129.9, 129.3, 128.7, 127.6, 126.2, 125.5, 117.3, 77.5, 65.2, 54.4, 38.8; MS (EI) m/z (relative intensity): 305 (M^+ , 2%); Anal. Calcd for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_2$: C, 70.81; H, 4.95; N, 13.76. Found: C, 70.78; H, 5.01; N, 13.49.

2-[(S)-(2-Oxo-4-phenyloxazolidin-3-yl)amino]-2-phenylacetonitrile (3e). From **2e** (53 mg, 0.2 mmol) by General Procedure B was obtained **3e** (27 mg, 46%) as a colorless solid; mp 176–178 $^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{23}$ $+60$ (c 0.06, CHCl_3); IR (film): 3263, 2982, 2903, 2227 (w), 1756, 1495, 1456, 1103, 1025 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.42-7.30 (m, 10H), 5.02 (d, $J = 4.9$ Hz, 1H), 4.97 (dd, $J = 8.2, 6.0$ Hz, 1H), 4.68 (dd, $J =$

8.5, 8.5 Hz, 1H), 4.30–4.28 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.1, 136.8, 131.3, 130.0, 129.4, 129.2, 128.3, 127.3, 118.3, 69.2, 62.1, 55.7; MS (EI) m/z (relative intensity): 293 (M^+ , 2%); Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2$: C, 69.61; H, 5.15; N, 14.33. Found: C, 69.73; H, 5.29; N, 14.32.

2-(Naphthalen-2-yl)-2-[(S)-(2-oxo-4-phenyloxazolidin-3-yl)amino]acetonitrile (3f). From **2f** (61 mg, 0.19 mmol) by General Procedure B was obtained **3f** (27 mg, 46%) as a colorless solid; mp 157–159 °C; $[\alpha]_{\text{D}}^{23} +49$ (c 0.07, CHCl_3); IR (film): 3280, 3060, 2923, 2852, 2252 (w), 1761, 1458, 1398, 1212, 1100, 1023 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.92 (s, 1H), 7.82–7.29 (m, 11H), 5.18 (d, J = 4.7 Hz, 1H), 4.97 (dd, J = 8.1, 6.0 Hz, 1H), 4.68 (dd, J = 8.7, 8.7 Hz, 1H), 4.41 (d, J = 6.2 Hz, 1H), 4.29 (dd, J = 8.9, 6.0 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.3, 143.9, 136.8, 133.7, 132.9, 129.4, 129.3, 129.2, 128.5, 128.3, 128.1, 127.7, 127.3, 127.0, 125.0, 118.3, 69.2, 62.2, 55.8; MS (EI) m/z (relative intensity): 343 (M^+ , 3%); Anal. Calcd for $\text{C}_{21}\text{H}_{17}\text{N}_3\text{O}_2$: C, 73.45; H, 4.99; N, 12.24. Found: C, 73.68; H, 4.91; N, 12.19.

2-[(S)-(2-Oxo-4-phenyloxazolidin-3-yl)amino]-2-(p-tolyl)acetonitrile (3g). From **2g** (56 mg, 0.2 mmol) by General Procedure B was obtained **3g** (21 mg, 34%) as a colorless solid; mp 122–125 °C; $[\alpha]_{\text{D}}^{20} +48$ (c 0.09, CHCl_3); IR (film): 3281, 3034, 2922, 2250 (w), 1762, 1608, 1528, 1458, 1399, 1358, 1264, 1100, 1023 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.39–7.30 (m, 7H), 7.14 (d, J = 7.6 Hz, 2H), 4.99–4.96 (m, 2H), 4.67 (dd, J = 8.9, 8.4 Hz, 1H), 4.28 (dd, J = 8.9, 5.9 Hz, 1H), 4.24 (d, J = 3.8 Hz, 1H), 2.32 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.1, 140.1, 136.9, 129.8, 129.3, 128.3, 128.2, 127.3, 118.5, 69.2, 62.1, 55.4, 21.2; MS (CI) m/z (relative intensity): 308 ($[\text{M}+1]^+$, 52%); Anal. Calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2$: C, 70.34; H, 5.58; N, 13.67. Found: C, 70.04; H, 5.83; N, 13.08.

2-(3-Nitrophenyl)-2-[(S)-(2-oxo-4-phenyloxazolidin-3-yl)amino]acetonitrile (3h). From **2h** (62 mg, 0.2 mmol) by General Procedure B was obtained **3h** (36 mg, dr = 1.5:1, 53%) as two separable diastereomers. **Major:** Colorless solid; mp 96–98 °C; $[\alpha]_{\text{D}}^{20} +58$ (c 0.05, CHCl_3); IR (film): 3300, 3093, 2922, 2857, 2232 (w), 1752, 1532, 1351, 1241, 1099, 1025 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.22–8.19 (m, 2H), 7.75 (d, J = 4.8 Hz, 1H), 7.76–7.21 (m, 6H), 5.10 (d, J = 5.2 Hz, 1H), 4.91 (dd, J = 8.8, 6.8 Hz, 1H), 4.67 (dd, J = 8.8, 8.5 Hz, 1H), 4.58 (d, J = 5.1 Hz, 1H), 4.30 (dd, J = 9.0, 6.7 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.5, 148.6, 136.1, 134.2, 133.6, 130.3, 129.6, 129.4, 127.4, 124.9, 123.4, 117.0, 69.2, 62.6, 54.8; MS (CI) m/z (relative intensity): 312 ($[\text{M}-\text{CN}]^+$, 100%); Anal. Calcd for $\text{C}_{17}\text{H}_{14}\text{N}_4\text{O}_4$: C, 60.35; H, 4.17; N, 16.56. Found: C, 60.07; H, 4.35; N, 16.42. **Minor:** Colorless solid; mp 125–127 °C; $[\alpha]_{\text{D}}^{23} +237$ (c 0.06, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 8.25 (d, J = 1.9 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 7.80 (dd, J = 8.0, 1.2 Hz, 1H), 7.56 (dd, J = 8.0, 8.0 Hz, 1H), 7.36–7.24 (m, 5H), 5.22 (d, J = 3.8 Hz, 1H), 4.67–4.62 (m, 2H), 4.53 (dd, J = 8.9, 8.4 Hz, 1H), 4.25 (dd, J = 9.0, 7.2 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.1, 148.5, 135.5, 134.6, 134.1, 130.1, 129.7, 129.3, 127.7, 124.7, 123.4, 116.4, 69.2, 63.0, 54.3; MS (CI) m/z (relative intensity): 312 ($[\text{M}-\text{CN}]^+$, 100%); Anal. Calcd for $\text{C}_{17}\text{H}_{14}\text{N}_4\text{O}_4$: C, 60.35; H, 4.17; N, 16.56. Found: C, 60.58; H, 4.23; N, 16.38.

2-(4-Methoxyphenyl)-2-[(S)-(2-oxo-4-phenyloxazolidin-3-yl)amino]acetonitrile (3i). From **2i** (60 mg, 0.2 mmol) by General Procedure B was obtained **3i** (2 mg, 5%) as a colorless oil; $[\alpha]_D^{20} +22$ (*c* 0.13, CHCl₃); IR (film): 3276, 2969, 2923, 2844, 2246, 1761, 1615, 1514, 1456, 1398, 1252, 1176, 1098, 1028 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.47-7.29 (m, 7H), 6.85 (d, *J* = 7.5 Hz, 2H), 5.02-4.97 (m, 2H), 4.68 (dd, *J* = 9.0, 8.4 Hz, 1H), 4.28 (dd, *J* = 9.0, 5.7 Hz, 1H), 4.24-4.20 (m, 1H), 3.77 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 160.6, 158.1, 136.9, 129.7, 129.3, 127.3, 123.7, 118.5, 114.5, 69.2, 62.1, 55.4, 55.1; MS (CI) *m/z* (relative intensity): 324 ([M+1]⁺, 36%); HRMS-FAB (*m/z*) [M+H]⁺ Calcd for C₁₈H₁₈N₃O₃, 324.1348; found, 324.1356.

2-[(S)-(2-Oxo-4-phenyloxazolidin-3-yl)amino]butyronitrile (3k). From **2k** (43 mg, 0.2 mmol) by General Procedure B was obtained **3k** (18 mg, dr = 2:1, 37%) as a colorless oil, separable 2:1 mixture of diastereomers; **Major:** $[\alpha]_D^{20} +38$ (*c* 0.65, CHCl₃); IR (film): 3283, 2975, 2929, 2877, 2252 (w), 1762, 1458, 1399, 1211, 1097, 1023 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.47-7.33 (m, 5H), 4.98 (dd, *J* = 8.1, 6.2 Hz, 1H), 4.65 (dd, *J* = 8.8, 8.1 Hz, 1H), 4.27 (dd, *J* = 8.8, 6.2 Hz, 1H), 4.15-4.10 (m, 1H), 3.81-3.79 (m, 1H), 1.69-1.61 (m, 2H), 0.99 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 158.1, 136.8, 129.4, 129.3, 127.4, 119.2, 69.1, 62.2, 53.4, 24.4, 9.7; MS (CI) *m/z* (relative intensity): 246 ([M+1]⁺, 43%); HRMS-FAB (*m/z*) [M+H]⁺ Calcd for C₁₃H₁₆N₃O₂, 246.1243; found, 246.1234. **Minor:** $[\alpha]_D^{20} +53$ (*c* 0.25, CHCl₃); IR (film): 3289, 2975, 2922, 2877, 2252 (w), 1762, 1453, 1394, 1212, 1091, 1023 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.28 (m, 5H), 4.89 (dd, *J* = 8.1, 6.2 Hz, 1H), 4.63 (dd, *J* = 8.8, 8.1 Hz, 1H), 4.30 (dd, *J* = 8.8, 6.2 Hz, 1H), 4.18 (br s, 1H), 3.88-3.78 (m, 1H), 1.79-1.71 (m, 2H), 1.03 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 158.9, 136.1, 129.6, 129.4, 127.7, 118.7, 68.9, 62.2, 53.2, 24.9, 9.9; MS (CI) *m/z* (relative intensity): 246 ([M+1]⁺, 32%); HRMS-FAB (*m/z*) [M+H]⁺ Calcd for C₁₃H₁₆N₃O₂, 246.1243; found, 246.1241.

3-Methyl-2-[(S)-(2-oxo-4-phenyloxazolidin-3-yl)amino]butyronitrile (3l). From **2l** (46 mg, 0.2 mmol) by General Procedure B was obtained **3l** (38 mg, dr = 3:1, 73%) as separable diastereomers. **Major:** Colorless solid; mp 98–100 °C; $[\alpha]_D^{23} +52$ (*c* 0.13, CHCl₃); IR (film): 3258, 2965, 2916, 2238 (w), 1758, 1459, 1408, 1364, 1245, 1106, 1025 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.33 (m, 5H), 4.96 (dd, *J* = 8.3, 6.1 Hz, 1H), 4.64 (dd, *J* = 8.8, 8.3 Hz, 1H), 4.28 (dd, *J* = 8.9, 6.1 Hz, 1H), 4.11 (d, *J* = 6.1 Hz, 1H), 3.69 (dd, *J* = 5.9, 5.9 Hz, 1H), 1.87-1.82 (m, 1H), 0.98 (d, *J* = 6.6 Hz, 3H), 0.91 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 158.1, 136.7, 129.4, 129.3, 127.4, 118.4, 69.0, 62.2, 58.4, 29.8, 19.1, 17.8; MS (EI) *m/z* (relative intensity): 259 (M⁺, 7%); Anal. Calcd for C₁₄H₁₇N₃O₂: C, 64.85; H, 6.61; N, 16.21. Found: C, 65.08; H, 6.47; N, 16.22. **Minor:** Colorless oil; $[\alpha]_D^{20} -15$ (*c* 0.02, CHCl₃); IR (film): 3286, 2966, 2955, 2259 (w), 1762, 1497, 1458, 1397, 1211, 1100, 1024 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.33 (m, 5H), 4.83 (dd, *J* = 8.2, 6.3 Hz, 1H), 4.61 (dd, *J* = 9.0, 8.2 Hz, 1H), 4.29 (dd, *J* = 8.2, 6.3 Hz, 1H), 4.21 (d, *J* = 4.8 Hz, 1H), 3.70 (dd, *J* = 5.8, 5.8 Hz, 1H), 1.99-1.93 (m, 1H), 1.04 (d, *J* = 6.7 Hz, 3H), 0.99 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 158.9, 136.1, 129.6, 129.3, 127.7,

117.6, 68.9, 62.3, 58.2, 29.8, 19.3, 17.8; MS (EI) m/z (relative intensity): 259 (M^+ , 11%); Anal. Calcd for $C_{14}H_{17}N_3O_2$: C, 64.85; H, 6.61; N, 16.21. Found: C, 65.15; H, 6.75; N, 15.94.

Stereochemical Proof for Strecker Product (3I). The major product (**3I**) was subjected to reduction conditions: A mixture of **3I** (major diastereomer, 36 mg, 0.14 mmol) and $BH_3 \cdot THF$ (4.2 mL, 1.0 M in THF, 4.2 mmol) in THF (3 mL) was heated to reflux. After 3 d, 3 M HCl (4 mL) was added to the mixture dropwise under ice-bath. The resulting mixture was stirred at 0 °C for 3 h, then at ambient temperature for 4 h. Solvent was removed and the residue was partitioned between basic brine and CH_2Cl_2 . The organic phase was washed with brine, dried ($MgSO_4$) and concentrated. 1H NMR showed that all **3I** had been consumed. To a solution of this crude mixture in MeOH (3 mL) was added $(Boc)_2O$ (250 mg, 1.1 mmol), $NaHCO_3$ (170 mg, 2.0 mmol) and water (0.3 mL). The mixture was sonicated for 90 min, stirred at ambient temperature overnight, filtered through celite, concentrated, and dried. Flash chromatography gave (*R*)-**4** (2 mg, 7% from **3I**) as a colorless oil; $[\alpha]_D^{25} +22$ (*c* 0.1, $CHCl_3$) (Lit.,²⁸ value for (*S*)-**4**: $[\alpha]_D^{25} -28.7$ (*c* 1.32, $CHCl_3$, 95% ee)). Spectral data matched the literature.²⁸

ACKNOWLEDGEMENTS

We thank NIH (R01 GM67817) for generous support.

REFERENCES (AND NOTES)

1. R. O. Duthaler, *Tetrahedron* 1994, **50**, 1539.
2. Several reviews contain extensive references to the earlier work: (a) C. Spino, *Angew. Chem., Int. Ed.*, 2004, **43**, 1764. (b) H. Groger, *Chem. Rev.*, 2003, **103**, 2795. (c) L. Yet, *Angew. Chem., Int. Ed.*, 2001, **40**, 875. (d) T. Vilaivan, W. Bhanthumnavin, and Y. Sritana-Anant, *Curr. Org. Chem.*, 2005, **9**, 1315. (e) Y. Ohfuné and T. Shinada *Eur. J. Org. Chem.*, 2005, 5127. (f) Y Takemoto, *Org. Biomol. Chem.*, 2005, **3**, 4299.
3. (a) M. S. Iyer, K. M. Gigstad, N. D. Namdev, and M. Lipton, *J. Am. Chem. Soc.*, 1996, **118**, 4910. (b) E. J. Corey and M. J. Grogan, *Org. Lett.*, 1999, **1**, 157. (c) P. Vachal and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2002, **124**, 10012. (d) Z. G. Jiao, X. M. Feng, B. Liu, F. X. Chen, G. L. Zhang, and Y. Z. Jiang, *Eur. J. Org. Chem.*, 2003, 3818. (e) J. K. Huang and E. J. Corey, *Org. Lett.*, 2004, **6**, 5027. (f) D. E. Fuerst and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2005, **127**, 8964.
4. T. Ooi, Y. Uematsu, and K. Maruoka, *J. Am. Chem. Soc.*, 2006, **128**, 2548.
5. M. S. Sigman and E. N. Jacobsen, *J. Am. Chem. Soc.*, 1998, **120**, 5315. (b) C. A. Krueger, K. W. Kuntz, C. D. Dzierba, W. G. Wirschun, J. D. Gleason, M. L. Snapper, and A. H. Hoveyda, *J. Am. Chem. Soc.*, 1999, **121**, 4284. (c) S. Nakamura, N. Sato, M. Sugimoto, and T. Toru, *Tetrahedron*:

- Asymmetry*, 2004, **15**, 1513. (d) M. Takamura, Y. Hamashima, H. Usuda, M. Kanai, and M. Shibasaki, *Angew. Chem. Int. Ed.*, 2000, **39**, 1650. (e) S. Masumoto, H. Usuda, M. Suzuki, M. Kanai, and M. Shibasaki, *J. Am. Chem. Soc.*, 2003, **125**, 5634.
6. (a) A. Fadel and A. Khesrani, *Tetrahedron: Asymmetry*, 1998, **9**, 305. (b) M. Truong, F. Lecornue, and A. Fadel, *Tetrahedron: Asymmetry*, 2003, **14**, 1063. (c) F.-J. Volk, M. Wagner, and A. W. Frahm, *Tetrahedron: Asymmetry*, 2003, **14**, 497.
7. V. Banphavichit, W. Mansawat, W. Bhanthumnavin, and T. Vilaivan, *Tetrahedron*, 2004, **60**, 10559.
8. (a) H. Kunz and W. Pfrengle, *J. Am. Chem. Soc.*, 1988, **110**, 651. (b) H. Kunz and W. Sager, *Angew. Chem., Int. Ed.*, 1987, **99**, 557. (c) H. Kunz, W. Sager, W. Pfrengle, and D. Schanzenbach, *Tetrahedron Lett.*, 1988, **29**, 4397. (d) R. Badorrey, C. Cativiela, M. D. Diaz-de-Villegas, R. Diez, F. Galbiati, and J. A. Galvez, *J. Org. Chem.*, 2005, **70**, 10102.
9. (a) F. A. Davis and K. R. Prasad, *J. Org. Chem.*, 2002, **67**, 7802. (b) B.-F. Li, K. Yuan, M.-J. Zhang, H. Wu, L.-X. Dai, Q.-R. Wang, and X.-L. Hou, *J. Org. Chem.*, 2003, **68**, 6264. (c) E. Takahashi, H. Fujisawa, T. Yanai, and T. Mukaiyama, *Chem. Lett.*, 2005, **34**, 604. (d) A. Avenoza, J. H. Busto, F. Corzana, J. M. Peregrina, D. Sucunza, and M. M. Zurbano, *Synthesis*, 2005, 575.
10. Y. Ohfuné and T. Shinada, *Bull. Chem. Soc., Jpn.*, 2003, **76**, 1115.
11. (a) W. H. J. Boesten, J.-P. Seerden, B. de Lange, H. J. A. Dielemans, H. L. M. Elsenberg, B. Kaptein, H. M. Moody, R. M. Kellogg, and Q. B. Broxterman, *Org. Lett.*, 2001, **3**, 1121. (b) R. Sakurai, S. Suzuki, J. Hashimoto, M. Baba, O. Itoh, A. Uchida, T. Hattori, S. Miyano, and M. Yamaura, *Org. Lett.*, 2004, **6**, 2241.
12. M. Sugiura and S. Kobayashi, *Angew. Chem., Int. Ed.*, 2005, **44**, 5176.
13. J. M. Keith and E. N. Jacobsen, *Org. Lett.*, 2004, **6**, 153.
14. For a review of dual activation, see: J.-A. Ma and D. Cahard, *Angew. Chem., Int. Ed.*, 2004, **43**, 4566.
15. H. Konishi, C. Ogawa, M. Sugiura, and S. Kobayashi, *Adv. Synth. Catal.*, 2005, **347**, 1899.
16. J. Y. Choi and Y. H. Kim, *Tetrahedron Lett.*, 1996, **37**, 7795.
17. D. Enders and M. Moser, *Tetrahedron Lett.*, 2003, **44**, 8479.
18. Y. Shen and G. K. Friestad, *J. Org. Chem.*, 2002, **67**, 6236.
19. J. Qin and G. K. Friestad, *Tetrahedron*, 2003, **59**, 6393.
20. (a) G. K. Friestad and H. Ding, *Angew. Chem., Int. Ed.*, 2001, **40**, 4491. (b) G. K. Friestad, C. S. Korapala, and H. Ding, *J. Org. Chem.*, 2006, **71**, 281.
21. Review: G. K. Friestad, *Eur. J. Org. Chem.*, 2005, 3157.
22. For application of *N*-acylhydrazones to radical addition, see: (a) G. K. Friestad and J. Qin, *J. Am. Chem. Soc.*, 2000, **122**, 8329. (b) G. K. Friestad, C. Draghici, M. Soukri, and J. Qin, *J. Org. Chem.*,

- 2005, **70**, 6330. (c) G. K. Friestad and J. Qin, *J. Am. Chem. Soc.*, 2001, **123**, 9922. (d) G. K. Friestad, A. M. Deveau, and J.-C. Marie, *Org. Lett.*, 2004, **6**, 3249.
23. (a) Radical addition: M. Fernández and R. Alonso, *Org. Lett.*, 2003, **5**, 2461. (b) Allylindium addition: G. R. Cook, B. C. Maity, and R. Kargbo, *Org. Lett.*, 2004, **6**, 1749. (c) Mannich-type reaction: M. F. Jacobsen, L. Ionita, and T. Skrydstrup, *J. Org. Chem.*, 2004, **69**, 4792.
24. Hf(OTf)₄ also promoted the addition (39% yield, dr 1.5:1).
25. A. S. Pilcher, H. L. Ammon, and P. DeShong, *J. Am. Chem. Soc.*, 1995, **117**, 5166. C. J. Handy, Y.-F. Lam, and P. DeShong, *J. Org. Chem.*, 2000, **65**, 3542.
26. Y. Shen and G. K. Friestad, *J. Org. Chem.*, 2002, **67**, 6236.
27. The N–N fragmentation product (**1e**) was observed in large amounts (ca. 1:1 with product) in the crude product mixture from **2h**. In the other reactions, **1** was observed only in small amounts (from **2e**, **2g**, **2j**, **2k**) or not at all (from **2a**, **2f**, **2i**, **2l**). No reduction in yield occurred when the reaction of **2e** is extended from 2 d (46%) to 7 d (48%). These observations suggest that diastereoselective decomposition, though not rigorously excluded, is unlikely to account for the high selectivity.
28. D. Enders and J. Wiedemann, *Synthesis*, 1996, 1443.
29. R. L. Shriner, R. C. Fuson, D. Y. Curtin, and T. C. Morrill, 'The Systematic Identification of Organic Compounds,' 6th ed, Wiley, New York, 1980, p. 325.